Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 753-759

  Hartung, Gernot ^a   Stehle, Gerd ^b   Sinn, Hannsjörg ^b   Wunder, Andreas ^b   Schrenk, Hans Hermann ^b   Heeger, Steffen ^b   Kränzle, Marion ^b   Edler, Lutz ^b   Frei, Eva ^b   Fiebig, Heinz Herbert ^b   Heene, Dieter Ludwig ^b   Maier Borst, Wolfgang ^b   Queisser, Wolfgang ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN CONJUGATE; METHOTREXATE ALBUMIN; METHOTREXATE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MALE; MESOTHELIOMA; NEUROFIBROSARCOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MESOTHELIOMA; METHOTREXATE; MIDDLE AGED; NEOPLASMS; PLEURAL NEOPLASMS; REMISSION INDUCTION; SERUM ALBUMIN; SPINAL CORD NEOPLASMS;

EID: 0032904067     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Seeger, D. R., Cosulich, D. B., Smith, J. M., and Hultquist, M. E. Analogs of pteroyl glutamic acid. III. 4-Amino derivatives. J. Am. Chem. Soc., 71: 1753-1755, 1949.
2. Hertz, R., Lewis, J., and Lipsett, M. B. Five years experience with the chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Am. J. Obstet. Gynecol., 82: 631-637, 1961.
3. Bertino, J. R. Ode to methotrexate. J. Clin. Oncol., 11: 5-14, 1993.
4. Kaye, S. B. New antimetabolites in cancer chemotherapy and their clinical impact. Br. J. Cancer, 78 (Suppl. 3): 1-7, 1998.
5. Chabner, B. A. Anticancer drugs. In: V. T. de Vita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 325-417. Philadelphia: J. R. Lippincott, 1993.
6. Evans, W. E., Crom, W. R., and Yalowich, J. C. Methotrexate. In: W. E. Evans, J. J. Schentag, W. J. Jusko, and H. Harrison (eds.), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, pp. 1009-1056. Spokane, WA: Applied Therapeutics, Inc., 1986.
7. Friberg, S., and Mattson, S. On the growth rates of human malignant tumors: implications for medical decision making. J. Surg. Oncol., 65: 284-297, 1997.
8. Jain, R. K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer and Metastasis Rev., 9: 253-266, 1990.
9. Peters, T. All About Albumin: Biochemistry, Genetics and Medical Applications. New York: Academic Press, 1996.
10. Andersson, C., Iresjo, B. M., and Lundholm, K. Identification of tissue sites for increased albumin degradation in sarcoma-bearing mice. J. Surg. Res., 50: 156-162, 1991.
11. Clorius, J. H., Sinn, H., Manke, H. G., Schrenk, H. H., Blatter, J., Werling, C., Friedrich, E. A., Voges, J., Bahner, M., Strum, V., Drings, P., and van Kaick, G. Serum albumin (SA) accumulation by bronchogenic tumours: a tracer technique may help with patient selection for SA-delivered chemotherapy. Eur. J. Nucl. Med., 22: 989-996, 1995.
12. Wunder, A., Stehle, G., Sinn, H., Schrenk, H. H., Hoff-Biederbeck, D., Bader, F., Friedrich, E. A., Peschke, P., Maier-Borst, W., and Heene, D. L. Enhanced albumin uptake by rat tumors. Int. J. Oncol., 11: 497-507, 1997.
13. Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Stewart, J. C. M., Hartung, G., Maier-Borst, W., and Heene, D. L. Plasma protein (albumin) catabolism by the tumor itself: implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol.-Hematol., 26: 77-100, 1997.
14. Magnenat, G., Schindler, R., and Isliker, H. Transport d'agents cytostatiques par les protéines plasmatiques. III. Activité antitumorale in vitro de conjugués cytostatique-azoprotéines. Eur. J. Cancer, 5: 33-40, 1969.
15. Jacobs, S. A., d'Urso-Scott, M., and Bertino, J. R. Some biochemical and pharmacologic properties of amethopterin-albumin. Ann. N. Y. Acad. Sci., 186: 284-286, 1971.
16. Chu, B. C. F., and Whiteley, J. M. High molecular weight derivatives of methotrexate as chemotherapeutic agents. Mol. Pharmacol., 13: 80-88, 1977.
17. Halbert, G. W., Florence, A. T., and Stuart, J. F. Characterization of in vitro drug release and biological activity of methotrexate-bovine serum albumin conjugates. J. Pharm. Pharmacol., 39: 871-876, 1987.
18. Bures, L., Lichy, A., Bostik, J., and Spundova, M. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. V. Alternative method for preparation of serum albumin-methotrexate derivative. Neoplasma (Bratisl.), 37: 225-231, 1990.
19. Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Schütt, S., Heene, D. L., and Maier-Borst, W. The loading rate determines tumor targeting of methotrexate-albumin conjugates in rats. Anticancer Drugs, 8: 677-685, 1997.
20. Stehle, G., Wunder, A., Sinn, H., Schrenk, H. H., Schütt, S., Frei, E., Hartung, G., Maier-Borst, W., and Heene, D. L. Pharmacokinetics of methotrexate-albumin conjugates in tumor bearing rats. Anticancer Drugs, 8: 835-844, 1997.
21. Wunder, A., Stehle, G., Schrenk, H. H., Hartung, G., Frei, E., Heene, D. L., Maier-Borst, W., and Sinn, H. Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinosarcoma. Int. J. Cancer, 76: 884-890, 1998.
22. Stehle, G., Wunder, A., Schrenk, H. H., Hartung, G., Heene, D. L., and Sinn, H. Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 Hi prostate cancer bearing rats. Anticancer Drugs, in press, 1999.
23. Fiebig, H. H., Roth, T., Hartung, G., Sinn, H., and Stehle, G. In vivo activity of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts. Eur. J. Cancer, 33: (Suppl. 8): S174, 1997.
24. Kreuser, E. D., Fiebig, H. H., Scheulen, M. E., Hanauske, A., Keppler, B. K., Mross, K., Schalhorn, A., Eisenbrand, G., Edler, L., Höffken, K., and Berdel, W. E. Standard operating procedures and organization of the German Phase I, II, III Study Groups, New Drug Development Group (AWO) and Study Group of Pharmacology in Oncology and Hematology (APOH) of the Association for Medical Oncology (AIO) of the German Cancer Society. Onkologie, 21 (Suppl. 2): 1-70, 1998.
25. Fiebig, H. H. Subacute toxicity study of MTX-HSA in mice. Freiburg, Germany: Oncotest GmbH, 1995.
26. Hartung, G., Heeger, S., Schrenk, H. H., Stehle, G., Sinn, H., and Queisser, W. Drug monitoring of methotrexate covalently bound to human serum albumin (MTX-HSA) with homogeneous enzyme multiplied immunoassay technique (EMIT) in a Phase I trial. Ann. Hematol., 73 (Suppl. II): A50, 1996.
27. Oellerich, M., Engelhardt, P., Schaadt, M., and Diehl, V. Determination of methotrexate in serum by a rapid, fully mechanized enzyme immunoassay (EMIT). J. Clin. Chem. Clin. Biochem., 18: 169-174, 1980.
28. Canobbio, L., Miglietta, L., and Boccardo, F. Medical treatment of advanced renal carcinoma: present options and future directions. Cancer Treat. Rev., 22: 85-104, 1996.
29. Hoogsteden, H. C., Lagerak, A. W., van der Kwast, T. H., Versnel, M. A., and van Gelder, T. Malignant pleura mesothelioma. Crit. Rev. Oncol. Hematol., 25: 97-126, 1997.
30. Solheim, O. P., Sæter, G., Finnanger, A. M., and Stenwig, A. E. High-dose methotrexate in the treatment of malignant mesothelioma of pleura. A Phase II study. Br. J. Cancer, 65: 956-960, 1992.